The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.
significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, a rare positive outcome in a field littered with failure.
gantenerumab and Eli Lilly's donanemab, are higher as a result of the Biogen-Eisai data, analysts said. Lilly said it remained confident in its donanemab development programme. Results of a key late-stage trial testing the drug are anticipated by mid-2023.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Alzheimer's drug slowed progression of the disease in Phase 3 trialThe Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness.
Leer más »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Leer más »
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNNA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Leer más »
Experimental Alzheimer's drug shows benefits in phase 3 trial, company saysJapanese drugmaker Eisai said cognitive function slowed over 18 months in patients who received the drug, called lecanemab.
Leer más »
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Leer más »
Alzheimer's-slowing drug labelled historicThe drug appears to reduce the pace of the disease, in early data from clinical trials.
Leer más »